Produktname:1-(((cyclohexyloxy)carbonyl)oxy)ethyl 3-((2'-(2-ethyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate

IUPAC Name:1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 3-{[2'-(2-ethyl-2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-2-oxo-2,3-dihydro-1H-1,3-benzodiazole-4-carboxylate

CAS:1185256-03-4
Molekulare Formel:C33H34N6O6
Reinheit:95%
Katalognummer:CM161094
Molekulargewicht:610.67

Packungseinheit Verfügbarer Vorrat Preis($) Menge

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1185256-03-4
Molekulare Formel:C33H34N6O6
Schmelzpunkt:-
SMILES-Code:O=C(C1=C(N2CC3=CC=C(C4=CC=CC=C4C5=NN(CC)N=N5)C=C3)C(NC2=O)=CC=C1)OC(OC(OC6CCCCC6)=O)C
Dichte:
Katalognummer:CM161094
Molekulargewicht:610.67
Siedepunkt:
Mdl-Nr.:
Lagerung:

Category Infos

Benzimidazoles
Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.
Tetrazoles
Tetrazoles are doubly unsaturated five-membered aromatic heterocycles consisting of one carbon atom and four nitrogen atoms. Tetrazole derivatives are a major class of heterocyclic compounds that are important for medicinal chemistry and drug design because of their not only isosteric properties with carboxylic acid and amide moieties, but also metabolic stability and other beneficial physicochemical properties.


Product Other Information

Product Overview 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil (DECC) is a novel synthetic compound that has recently been studied for its potential pharmacological applications. DECC is an angiotensin II receptor blocker (ARB) that has been developed to provide therapeutic benefits in the treatment of hypertension and other cardiovascular diseases. The compound is a prodrug, which means that it is inactive until it is metabolized in the body and converted into its active form. DECC has been found to possess a wide range of pharmacological activities, including anti-inflammatory, anti-oxidant, and anti-platelet activities. 
Synthesis Method 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is synthesized through a multi-step process involving the synthesis of the parent compound, candesartan cilexetil (CC), followed by the introduction of the 2-desethoxy-2-oxo-2H-2-ethyl moiety. The synthesis of CC involves the reaction of 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid with the amine 4-amino-2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid. The 2-desethoxy-2-oxo-2H-2-ethyl moiety is then introduced to the CC molecule by the reaction of the CC with 2-ethoxy-2-oxo-2H-2-ethyl acetate in the presence of a base.
Synthesis and Application 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil has been studied for its potential pharmacological applications, particularly in the treatment of hypertension and other cardiovascular diseases. Studies have shown that 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is a potent angiotensin II receptor blocker (ARB) with a high affinity for the AT1 receptor subtype. 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil is also a highly lipophilic compound that is rapidly absorbed and distributed throughout the body. This makes it an ideal candidate for the treatment of hypertension and other cardiovascular diseases, as it can be quickly and effectively delivered to the target sites in the body.
Future Directions The potential future directions for 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil include further research into its pharmacological applications, particularly in the treatment of hypertension and other cardiovascular diseases. Additionally, further research into the biochemical and physiological effects of 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil could yield new therapeutic applications for the drug. Additionally, further research into the mechanism of action of 2-Desethoxy-2-oxo-2H-2-ethyl candesartan cilexetil could reveal new therapeutic.